Fitorpey Docket No.: 6004.200-US

TECH CENTER 160012900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Belghuith et al.

Serial No.: 09/383,318

Group Art Unit: 1652

Filed: August 26, 1999

Examiner: Slobodyansky

For: Polypeptides Having Glucose Isomerase Activity And Nucleic Acids Encoding Same

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Assistant Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

- Amendment Fee Transmittal (in duplicate)
- Amendment 2.
- 3. Sequence Listing
- Disk Containing Sequence Listing
- Certified Copy of Tunisian Priority Application

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

> Asst. Commissioner for Patents Washington, DC 20231

on August 9, 2000.

Gina Maldonado

(name of person mailing paper)

(signature of person mailing paper)

09383318

08/14/2000 AZERGAW1 00000010 141447

01 FC:115

Attorney Docket No.: 6004.200-US

RECEIVED

AUG 17 2000

TECH CENTER 1600/2900 ATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Belghuith et al.

Serial No.: 09/383,318

Group Art Unit: 1652

Filed: August 26, 1999

Examiner: Slobodyansky

For: "Polypeptides Having Glucose Isomerase Activity And Nucleic Acids Encoding Same"

AMENDMENT FEE TRANSMITTAL

Assistant Commissioner for Patents Washington, DC 20231

Sir:

Transmitted herewith is an Amendment for the above-identified application in response to the Office Action mailed April 26, 2000.

It is respectfully requested that the time for response to the Office Action dated April 26, 2000 be extended for a period of 1 month from July 26, 2000 to August 26, 2000. The required fee for the extension is estimated to be \$110.

No additional claims fee is required.

Please charge the required extension and claims fees, estimated to be \$110, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: August 4, 2000

Reza Green, Reg. No. 38,475

Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400

New York, NY 10174-6401

(212) 867-0123

